Maria Wollbratt

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects

Troy C. Sarich, Michael Wolzt, Ulf G. Eriksson et al. · Journal of the American College of Cardiology · 2003 · 63 citations

Thrombin Generation, Thrombosis, Thrombopoiesis +13

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

Troy C. Sarich, Renli Teng, Gary Peters et al. · Clinical Pharmacokinetics · 2003 · 61 citations

Obesity, Metabolic Syndrome, Active Form +5

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

Michael Wolzt, Maria Wollbratt, Mia Svensson et al. · European Journal of Clinical Pharmacology · 2003 · 40 citations

Thrombosis, Healthy Subjects, Cardiovascular Disease +11

No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers

Troy C. Sarich, Kajs‐Mariey Schützer, Maria Wollbratt et al. · The Journal of Clinical Pharmacology · 2004 · 26 citations

Thrombosis, Digoxin Auc, Healthy Volunteers +10

Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp

Hans Ericsson, Daniel Röshammar, Maria Wollbratt et al. · International Journal of Clinical Pharmacology and Therapeutics · 2012 · 22 citations